One would think that with all this post data CKD & CFD released from the BETONMACE trial other than just barely missing the Primary topline data  all major BP would be jumping to take a chance on owning this IP to move the trials to commercialization , especially if we get FDA/EMA breakthrough status, 

I went back about a year on a research report that came out from Makula Fund management that I reread and it really opened my eyes on the huge potentially forthcoming for RVX in the short term,IMO  Althought the primary endpoint was not met the secondary endpoint sub analysis data was very positive and worthy of a BP deal  Here it is below, its worth a reread, yet here we languish at $1.40 , its unthinkable how low the market valuation at this point 

https://www.hvst.com/organization/makalu-fund-management/posts/resverlogix-corp-rvx-cn-the-making-of-a-mini-humira-oY5TBj9G